Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Eva Zhang^#^{1

2}, Thi H O Nguyen^#³, Lilith F Allen³, Lukasz Kedzierski^{3

4}, Louise C Rowntree³, So Young Chang³, Wuji Zhang³, Jennifer R Habel³, Isabelle J Foo³, Tejas Menon³, Jeni Mitchell¹, Rupert W Leong², Katherine Bond^{5

6}, Deborah A Williamson^{6

7

8}, Katherine Kedzierska^{3

9}, Britt Christensen^{10

11}

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
² Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
³ Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁴ Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
⁵ Department of Microbiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁶ Victorian Infectious Disease Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁷ Infectious Diseases, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
⁸ Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁹ Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hokkaido, Japan.
¹⁰ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia Britt.Christensen@mh.org.au.
¹¹ Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

^# Contributed equally.

PMID: 36878683
DOI: 10.1136/gutjnl-2022-329136

Comment

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Eva Zhang et al. Gut. 2024.

. 2024 Mar 7;73(4):712-714.

doi: 10.1136/gutjnl-2022-329136.

Authors

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
² Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
³ Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁴ Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
⁵ Department of Microbiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁶ Victorian Infectious Disease Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁷ Infectious Diseases, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
⁸ Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁹ Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hokkaido, Japan.
¹⁰ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia Britt.Christensen@mh.org.au.
¹¹ Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

^# Contributed equally.

PMID: 36878683
DOI: 10.1136/gutjnl-2022-329136

No abstract available

Keywords: COVID-19; IMMUNE RESPONSE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; TNF.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Kennedy NA, et al. Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28. Gut. 2023. PMID: 35902214

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Affiliations

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous